Purchase this article with an account.
Orly Gal-Or, Assaf Dotan, Mor Dachbash, Yael Nisgav, Dov Weinberger, Rita Ehrlich, Tami Livnat; Presence of bevacizumab in the iridocorneal angle following intravitreal injection in a rat model. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3270.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intravitreal anti vascular endothelial growth factor agents can cause sustained ocular hypertension in treated eyes. Our purpose was to investigate and characterize the presence of intravitreally injected Bevacizumab in the iridocorneal angle in a rat model.
Choroidal neovascularization was induced by diode laser photocoagulation on the right eye of twelve Brown Norway rats.<br /> Bevacizumab (25mg/ml) was injected intravitreally following 3 days.<br /> Immediately after Bevacizumab injection and 3,6,24 and 48 hours later, animals were euthanized for immunohfluorescence staining.<br /> Donkey anti-human IgG labeled with Alexa Fluor® 488 was used for Bevacizumab immunoreactivity detection. Anti CD31 antibody was used as a marker for schlemm's canal's (SC) endothelial cells.<br /> Untreated eyes were used as negative controls. We qualitatively analyzed the intensity of the immunohistochemistry staining.
Bevacizumab immunoreactivity was found in the Trabecular Meshwork (TM) and Schlemm's canal (SC) immediately after injection, and declined in a decremented manner within the following hours.<br /> Forty eight hours from the injection no bevacizumab staining was detected in the iridocorneal angle structures.
Our study demonstrated Bevacizumab in iridocorneal angle structures after intravitreal injection in a rat model.<br /> Bevacizumab molecules were shown to pass within 48 hours through the iridocorneal angle starting immediately after intravitreal bevacizumab injection.
This PDF is available to Subscribers Only